Infliximab
- IVInfliximabRemicadeChimaeric monoclonal antibody to TNF
Mechanism of Action
- Inhibits tumour necrosis factor alpha (TNF-α), a cytokine involved in systemic inflammation and the acute phase response.
Clinical Use
- Indications
- Moderate to severe rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Severe refractory ulcerative colitis
- Severe refractory Crohn's disease
- Psoriasis
- Adverse Effects
- Severe infections
- Reactivation of tuberculosis
- Anaemia
- Headache
- Nausea / diarrhoea
- Exacerbation of congestive cardiac failure
- Demyelinating disease